# Psilocybin for the Treatment of Cluster Headache

> **NCT02981173** · PHASE1 · COMPLETED · sponsor: **Yale University** · enrollment: 25 (actual)

## Conditions studied

- Cluster Headache

## Interventions

- **DRUG:** 0.143 mg/kg Psilocybin or 10 mg Psilocybin
- **DRUG:** 0.0143 mg/kg Psilocybin or 1 mg Psilocybin
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02981173
- **Lead sponsor:** Yale University
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-12-05
- **Primary completion:** 2022-06-30
- **Final completion:** 2022-10-21
- **Target enrollment:** 25 (ACTUAL)
- **Last updated:** 2023-12-15

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02981173

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02981173, "Psilocybin for the Treatment of Cluster Headache". Retrieved via AI Analytics 2026-09-15 from https://api.ai-analytics.org/clinical/NCT02981173. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*